Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has a cash flow conversion efficiency ratio of -0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-21.56 Million ≈ $-3.15 Million USD) by net assets (CN¥1.03 Billion ≈ $151.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688117 net asset quality score to measure how much of total assets are equity-financed.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ibotta, Inc.
NYSE:IBTA
|
0.066x |
|
Jiujiang Shanshui Technology Co.Ltd
SHE:301190
|
-0.002x |
|
Echo Investment SA
WAR:ECH
|
0.140x |
|
Farglory FTZ Investment Holding Co Ltd
TW:5607
|
0.041x |
|
Kido Group Corp
VN:KDC
|
0.061x |
|
Taiwan Sakura Corp
TW:9911
|
0.059x |
|
Zhejiang Narada Power Source
SHE:300068
|
0.321x |
|
Sinotherapeutics Inc. A
SHG:688247
|
N/A |
Annual Cash Flow Conversion Efficiency for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual cash flow conversion efficiency of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 688117 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥918.32 Million ≈ $134.38 Million |
CN¥25.27 Million ≈ $3.70 Million |
0.028x | -72.01% |
| 2023-12-31 | CN¥880.10 Million ≈ $128.79 Million |
CN¥86.53 Million ≈ $12.66 Million |
0.098x | -14.99% |
| 2022-12-31 | CN¥826.74 Million ≈ $120.98 Million |
CN¥95.62 Million ≈ $13.99 Million |
0.116x | +73.26% |
| 2021-12-31 | CN¥785.14 Million ≈ $114.89 Million |
CN¥52.41 Million ≈ $7.67 Million |
0.067x | -63.87% |
| 2020-12-31 | CN¥437.57 Million ≈ $64.03 Million |
CN¥80.84 Million ≈ $11.83 Million |
0.185x | +124.95% |
| 2019-12-31 | CN¥376.46 Million ≈ $55.09 Million |
CN¥30.92 Million ≈ $4.52 Million |
0.082x | -59.40% |
| 2018-12-31 | CN¥327.35 Million ≈ $47.90 Million |
CN¥66.23 Million ≈ $9.69 Million |
0.202x | -16.00% |
| 2017-12-31 | CN¥241.74 Million ≈ $35.37 Million |
CN¥58.22 Million ≈ $8.52 Million |
0.241x | -- |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more